Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Ritonavir"
topic_facet:"Randomized Controlled Trial"
journalStr:"The Lancet. Infectious diseases"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Ritonavir%22&filter%5B%5D=topic_facet%3A%22Randomized+Controlled+Trial%22&filter%5B%5D=journalStr%3A%22The+Lancet.+Infectious+diseases%22&lookfor=%22%2ARitonavir%22&type=Subject
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Ritonavir%22&filter%5B%5D=topic_facet%3A%22Randomized+Controlled+Trial%22&filter%5B%5D=journalStr%3A%22The+Lancet.+Infectious+diseases%22&lookfor=%22%2ARitonavir%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Ritonavir%22&filter%5B%5D=topic_facet%3A%22Randomized+Controlled+Trial%22&filter%5B%5D=journalStr%3A%22The+Lancet.+Infectious+diseases%22&lookfor=%22%2ARitonavir%22&type=Subject
PubPharm (8)
1
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV) : an open-label, phase 2, randomised, controlled, adaptive trial
enthalten in:
The Lancet. Infectious diseases
| 2024
von
Schilling, W.
|
Jittamala, P.
|
Watson, J.
| +89
ErratumIn: Lancet Infect Dis. 2023 Dec;23(12):e511. - PMID 37839427
Wird geladen...
2
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST) : 144-week follow-up results from a randomised controlled trial
enthalten in:
The Lancet. Infectious diseases
| 2018
von
Hakim, J.
|
Thompson, J.
|
Kityo, C.
| +114
CommentIn: Lancet Infect Dis. 2018 Jan;18(1):3-5. - PMID 29108798
Wird geladen...
3
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE) : a randomised, open-label, non-inferiority trial
enthalten in:
The Lancet. Infectious diseases
| 2015
von
Arribas, J.
|
Girard, P.
|
Landman, R.
| +118
CommentIn: Lancet Infect Dis. 2015 Jul;15(7):748-9. - PMID 26062879
Wird geladen...
4
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT) : 48 week results from a randomised, open-label, non-inferiority trial
enthalten in:
The Lancet. Infectious diseases
| 2015
von
Perez-Molina, J.
|
Rubio, R.
|
Rivero, A.
| +114
CommentIn: Lancet Infect Dis. 2015 Jul;15(7):748-9. - PMID 26062879
Wird geladen...
5
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI) : 48 week results of a randomised, open-label, phase 3b, non-inferiority trial
enthalten in:
The Lancet. Infectious diseases
| 2014
von
Arribas, J.
|
Pialoux, G.
|
Gathe, J.
| +7
CommentIn: Lancet Infect Dis. 2014 Jul;14(7):537-40. - PMID 24908549
Wird geladen...
6
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection : 48 week results of the randomised, open label, non-inferiority GARDEL trial
enthalten in:
The Lancet. Infectious diseases
| 2014
von
Cahn, P.
|
Andrade-Villanueva, J.
|
Arribas, J.
| +45
CommentIn: Lancet Infect Dis. 2014 Jul;14(7):535-7. - PMID 24783987
Wird geladen...
7
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen : long-term follow-up of a randomised, open-label trial
enthalten in:
The Lancet. Infectious diseases
| 2012
von
Kuhn, L.
|
Coovadia, A.
|
Strehlau, R.
| +9
CommentIn: Lancet Infect Dis. 2012 Jul;12(7):498-9. - PMID 22424721
Wird geladen...
8
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor : randomised, double-blind, phase 3, non-inferiority study
enthalten in:
The Lancet. Infectious diseases
| 2012
von
Molina, J.
|
Lamarca, A.
|
Andrade-Villanueva, J.
| +108
CommentIn: Lancet Infect Dis. 2012 Jan;12(1):3-5. - PMID 22015078
Wird geladen...
1
[1]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Ritonavir
Filter aufheben
Thema: Randomized Controlled Trial
Filter aufheben
Zeitschrift: The Lancet. Infectious diseases
Medienart
8
Aufsätze
8
E-Artikel
8
E-Ressourcen
Zeitschriftentitel
The Lancet. Infectious diseases
Thema
8
Journal Article
8
O3J8G9O825
Randomized Controlled Trial
Ritonavir
7
Anti-HIV Agents
7
Research Support, Non-U.S. Gov't
6
Multicenter Study
5
2494G1JF75
5
HIV Protease Inhibitors
5
Lopinavir
4
Reverse Transcriptase Inhibitors
3
0W860991D6
3
2T8Q726O95
3
Comparative Study
3
Deoxycytidine
3
Emtricitabine
3
G70B4ETF4S
3
Lamivudine
3
RNA, Viral
2
43Y000U234
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
1
2020-
7
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
8
Englisch
Haven't found what you're looking for?
Wird geladen...